Semaglutide: A Potential Game-Changer for Type 1 Diabetes Treatment

A small study conducted at the University at Buffalo has found that treating newly diagnosed type 1 diabetes patients with semaglutide may significantly reduce or eliminate their need for injected insulin. The study involved 10 patients who were treated with semaglutide while also taking meal-time and basal insulin. Within three months, all mealtime insulin doses were eliminated, and within six months, basal insulin was eliminated in 7 out of 10 patients. The patients' average blood sugar levels improved, and the most common side effects were nausea and vomiting. Further research is needed to validate these findings, but if confirmed, it could be a significant advancement in type 1 diabetes treatment.